Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
A Phase 3 Trial of Brepocitinib in Dermatomyositis.
Journal: The New England journal of medicine
Published: March 30, 2026
A Phase 3 Trial of Brepocitinib in Dermatomyositis.
Journal: The New England journal of medicine
Published: March 30, 2026
The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trial.
Journal: Arthritis research & therapy
Published: March 11, 2025
Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment.
Journal: Annals of the rheumatic diseases
Published: December 29, 2023
Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study.
Journal: Annals of the rheumatic diseases
Published: April 27, 2022
Depression-, Pain-, and Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus.
Journal: International journal of rheumatology
Published: January 05, 2022
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study.
Journal: Annals of the rheumatic diseases
Published: August 31, 2020
Anti-NR2 antibodies, blood-brain barrier, and cognitive dysfunction.
Journal: Clinical rheumatology
Published: February 10, 2016
Non-criteria anti-phospholipid antibodies and cognitive impairment in SLE.
Journal: Clinical rheumatology
Published: July 18, 2015
Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.
Journal: The Journal of rheumatology
Published: July 17, 2012
Last Updated: 09/26/2026